|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Atkinson RL, Yang WT, Rosen DG, Landis MD,
Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA,
et al: Cancer stem cell markers are enriched in normal tissue
adjacent to triple negative breast cancer and inversely correlated
with DNA repair deficiency. Breast Cancer Res. 15:R772013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geng SQ, Alexandrou AT and Li JJ: Breast
cancer stem cells: Multiple capacities in tumor metastasis. Cancer
Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Collina F, Di Bonito M, Li Bergolis V, De
Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M and Botti
G: Prognostic value of cancer stem cells markers in triple-negative
breast cancer. BioMed Res Int. 2015:1586822015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Resetkova E, Reis-Filho JS, Jain RK, Mehta
R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1
in breast cancer: A story of stem cells and tumor microenvironment.
Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Charafe-Jauffret E, Ginestier C, Bertucci
F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen
TT, Monville F, et al: ALDH1-positive cancer stem cells predict
engraftment of primary breast tumors and are governed by a common
stem cell program. Cancer Res. 73:7290–7300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alamgeer M, Ganju V, Kumar B, Fox J, Hart
S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky ME,
et al: Changes in aldehyde dehydrogenase-1 expression during
neoadjuvant chemotherapy predict outcome in locally advanced breast
cancer. Breast Cancer Res. 16:R442014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marcato P, Dean CA, Liu RZ, Coyle KM,
Bydoun M, Wallace M, Clements D, Turner C, Mathenge EG, Gujar SA,
et al: Aldehyde dehydrogenase 1A3 influences breast cancer
progression via differential retinoic acid signaling. Mol Oncol.
9:17–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pires BR, DE Amorim ÍS, Souza LD,
Rodrigues JA and Mencalha AL: Targeting cellular signaling pathways
in breast cancer stem cells and its implication for cancer
treatment. Anticancer Res. 36:5681–5691. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takebe N, Miele L, Harris PJ, Jeong W,
Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, Hedgehog, and
Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin
Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
20
|
Krakhmal NV, Zavyalova MV, Denisov EV,
Vtorushin SV and Perelmuter VM: Cancer invasion: Patterns and
mechanisms. Acta Naturae. 7:17–28. 2015.PubMed/NCBI
|
|
21
|
Shaw FL, Harrison H, Spence K, Ablett MP,
Simões BM, Farnie G and Clarke RB: A detailed mammosphere assay
protocol for the quantification of breast stem cell activity. J
Mammary Gland Biol Neoplasia. 17:111–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harrison H, Farnie G, Howell SJ, Rock RE,
Stylianou S, Brennan KR, Bundred NJ and Clarke RB: Regulation of
breast cancer stem cell activity by signaling through the Notch4
receptor. Cancer Res. 70:709–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Londoño-Joshi AI, Oliver PG, Li Y, Lee CH,
Forero-Torres A, LoBuglio AF and Buchsbaum DJ: Basal-like breast
cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.
Breast Cancer Res Treat. 133:437–445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang LY, Zhang XL, Du P and Zheng JH:
γ-Secretase inhibitor, DAPT inhibits self-renewal and stemness
maintenance of ovarian cancer stem-like cells in vitro. Chin J
Cancer Res. 23:140–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olsauskas-Kuprys R, Zlobin A and Osipo C:
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther.
6:943–955. 2013.PubMed/NCBI
|
|
26
|
Imatani A and Callahan R: Identification
of a novel NOTCH-4/INT-3 RNA species encoding an activated gene
product in certain human tumor cell lines. Oncogene. 19:223–231.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stylianou S, Clarke RB and Brennan K:
Aberrant activation of notch signaling in human breast cancer.
Cancer Res. 66:1517–1525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stoeck A, Lejnine S, Truong A, Pan L, Wang
H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, et al:
Discovery of biomarkers predictive of GSI response in
triple-negative breast cancer and adenoid cystic carcinoma. Cancer
Discov. 4:1154–1167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhong Y, Shen S, Zhou Y, Mao F, Lin Y,
Guan J, Xu Y, Zhang S, Liu X and Sun Q: NOTCH1 is a poor prognostic
factor for breast cancer and is associated with breast cancer stem
cells. OncoTargets Ther. 9:6865–6871. 2016. View Article : Google Scholar
|
|
30
|
Gupta S, Takebe N and Lorusso P: Targeting
the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2:237–250.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beachy PA, Hymowitz SG, Lazarus RA, Leahy
DJ and Siebold C: Interactions between Hedgehog proteins and their
binding partners come into view. Genes Dev. 24:2001–2012. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Varjosalo M and Taipale J: Hedgehog:
Functions and mechanisms. Genes Dev. 22:2454–2472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mullor JL, Sánchez P and Ruiz i Altaba A:
Pathways and consequences: Hedgehog signaling in human disease.
Trends Cell Biol. 12:562–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ng JMY and Curran T: The Hedgehog's tale:
Developing strategies for targeting cancer. Nat Rev Cancer.
11:493–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz
DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA and Lagasse E: A
stochastic model for cancer stem cell origin in metastatic colon
cancer. Cancer Res. 68:6932–6941. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amakye D, Jagani Z and Dorsch M:
Unraveling the therapeutic potential of the Hedgehog pathway in
cancer. Nat Med. 19:1410–1422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moraes RC, Zhang X, Harrington N, Fung JY,
Wu MF, Hilsenbeck SG, Allred DC and Lewis MT: Constitutive
activation of smoothened (SMO) in mammary glands of transgenic mice
leads to increased proliferation, altered differentiation and
ductal dysplasia. Development. 134:1231–1242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sandhiya S, Melvin G, Kumar SS and Dkhar
SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol
Pharmacother. 4:4–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rudin CM, Hann CL, Laterra J, Yauch RL,
Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et
al: Treatment of medulloblastoma with hedgehog pathway inhibitor
GDC-0449. N Engl J Med. 361:1173–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Von Hoff DD, LoRusso PM, Rudin CM, Reddy
JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, et
al: Inhibition of the hedgehog pathway in advanced basal-cell
carcinoma. N Engl J Med. 361:1164–1172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ
and Carson DA: Salinomycin inhibits Wnt signaling and selectively
induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl
Acad Sci USA. 108:13253–13257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Smalley MJ and Dale TC: Wnt signalling in
mammalian development and cancer. Cancer Metastasis Rev.
18:215–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schlange T, Matsuda Y, Lienhard S, Huber A
and Hynes NE: Autocrine WNT signaling contributes to breast cancer
cell proliferation via the canonical WNT pathway and EGFR
transactivation. Breast Cancer Res. 9:R632007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hernandez-Vargas H, Ouzounova M, Le
Calvez-Kelm F, Lambert MP, McKay-Chopin S, Tavtigian SV, Puisieux
A, Matar C and Herceg Z: Methylome analysis reveals Jak-STAT
pathway deregulation in putative breast cancer stem cells.
Epigenetics. 6:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buchert M, Burns CJ and Ernst M: Targeting
JAK kinase in solid tumors: Emerging opportunities and challenges.
Oncogene. 35:939–951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tavallai M, Booth L, Roberts JL,
Poklepovic A and Dent P: Rationally repurposing ruxolitinib (Jakafi
(®)) as a solid tumor therapeutic. Front Oncol.
6:1422016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aktas CC, Zeybek ND and Piskin AK: In
vitro effects of phenytoin and DAPT on MDA-MB-231 breast cancer
cells. Acta Biochim Biophys Sin (Shanghai). 47:680–686. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kai M, Kanaya N, Wu SV, Mendez C, Nguyen
D, Luu T and Chen S: Targeting breast cancer stem cells in
triple-negative breast cancer using a combination of LBH589 and
salinomycin. Breast Cancer Res Treat. 151:281–294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stover DG, Gil Del Alcazar CR, Brock J,
Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R,
et al: Phase II study of ruxolitinib, a selective JAK1/2 inhibitor,
in patients with metastatic triple-negative breast cancer. NPJ
Breast Cancer. 4:102018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rai G, Suman S, Mishra S and Shukla Y:
Evaluation of growth inhibitory response of Resveratrol and
Salinomycin combinations against triple negative breast cancer
cells. Biomed Pharmacother. 89:1142–1151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Habib JG and O'Shaughnessy JA: The
hedgehog pathway in triple-negative breast cancer. Cancer Med.
5:2989–3006. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Robarge KD, Brunton SA, Castanedo GM, Cui
Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay
J, et al: GDC-0449-a potent inhibitor of the hedgehog pathway.
Bioorg Med Chem Lett. 19:5576–5581. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Luistro L, He W, Smith M, Packman K,
Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W,
Hilton H, et al: Preclinical profile of a potent gamma-secretase
inhibitor targeting notch signaling with in vivo efficacy and
pharmacodynamic properties. Cancer Res. 69:7672–7680. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fan X, Khaki L, Zhu TS, Soules ME, Talsma
CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al: NOTCH pathway
blockade depletes CD133-positive glioblastoma cells and inhibits
growth of tumor neurospheres and xenografts. Stem Cells. 28:5–16.
2010.PubMed/NCBI
|
|
57
|
Antoszczak M and Huczyński A: Anticancer
Activity of Polyether Ionophore-Salinomycin. Anticancer Agents Med
Chem. 15:575–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang Q, Zhang C, He J, Guo Q, Hu D, Yang
X, Wang J, Kang Y, She R, Wang Z, et al: STAT3 inhibitor stattic
enhances radiosensitivity in esophageal squamous cell carcinoma.
Tumour Biol. 36:2135–2142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Plosker GL: Ruxolitinib: A review of its
use in patients with myelofibrosis. Drugs. 75:297–308. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vannucchi AM, Kiladjian JJ, Griesshammer
M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee
P, Mesa R, et al: Ruxolitinib versus standard therapy for the
treatment of polycythemia vera. N Engl J Med. 372:426–435. 2015.
View Article : Google Scholar : PubMed/NCBI
|
